Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

US11066475B2 · kind B2 · utility

Assignees

• Juno Therapeutics, Inc. · US
• Memorial Sloan Kettering Cancer Center · US

Inventors

• Blythe SATHER · South San Francisco, US
• Eric Smith · New York, US
• Rupesh Amin · Seattle, US
• Aye CHEN · Seattle, US
• Kimberly HARRINGTON · Seattle, US
• Collin HAUSKINS · Seattle, US
• Erik Hess · Seattle, US
• Cyr Clovis Chua DE IMUS · Kenmore, US
• Jon JONES · Seattle, US
• Audrey Olshefsky · Seattle, US
• Stefan Ponko · Seattle, US
• Ruth Salmon · Bainbridge Island, US
• Semih U. Tareen · Seattle, US
• Rebecca Wu · Seattle, US
• Yan Chen · Santa Clara, US
• Steven M. Shamah · Acton, US
• Csaba Pazmany · Belmont, US
• Jui Dutta-Simmons · Framingham, US
• Mariana Cota STIRNER · Seattle, US
• Melissa WORKS · Seattle, US

Key dates

• Filing date: Nov 1, 2018
• Grant date: Jul 20, 2021
• Expiry date: Mar 30, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.